Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab for corticosteroid-refractory polymyalgia rheumatica
2006-001081-16Phase 3Active
- Sponsor
- Victor MartÃnez Taboada
- Start
- Dec 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, double-blind trial of infliximab in polymyalgia rheumatica (PMR) (2 arms), sponsored by Victor MartÃnez Taboada. Primary endpoint: Steroid-free complete remission at week 24. Started Dec 2007; status: active.
02
Drugs
infliximab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on 2006-001081-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001081-16.